bioAffinity Technologies, Inc. consummated a best efforts public offering of 1,040,000 shares of common stock at $0.80 per share and pre-funded warrants to purchase up to 2,960,000 shares of common stock at $0.793 per warrant. The aggregate gross proceeds from the offering were approximately $3.2 million. The company intends to use the proceeds for working capital and general corporate purposes. bioAffinity Technologies, Inc. is a medical technology company that develops and commercializes commercializing diagnostic tools for cancer detection and cancer management.
